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Abstract: Increasing dependence on advanced technologies in the 21st century has created 
a dilemma between the practice and business of medicine. From information technology to 
robotic surgery, new technologies have expanded treatment possibilities and have potentially 
improved patient outcomes and safety. Simultaneously, their escalating costs limit access for 
certain patients and health care facilities. Nevertheless, medical decisions should not simply 
be based on cost. Input from physicians and other health care specialists as well as adherence 
to best practice position statements, are vital to implementing truly cost-effective strategies 
in medicine. Bronchial thermoplasty (BT), a US Food and Drug Administration approved 
bronchoscopy procedure in difficult-to-control persistent asthma, is a prime example of a new 
technology facing cost and implementation challenges. We discuss the specific indications and 
contraindications for BT and review recent real-world experiences that can provide the foundation 
for building a comprehensive asthma program that provides BT for difficult-to-control asthma 
patients who fail national guideline treatment recommendations after an adequate clinical trial 
of one. We also offer insight into the barriers to implementing a successful BT program and 
strategies for overcoming them.
Keywords: asthma, severe asthma, severe refractory asthma, biologic resistant asthma, BT
Introduction
Historians will debate the pros and cons of incorporating information technologies and 
computer science into the practice and business of medicine in the 21st century. The 
proliferation, assimilation and dependence on new technologies affect all disciplines 
in medicine. Implementation of such technological advances should be based on a 
careful analysis of cost–benefit ratios and safety. Few technological interventions are 
as controversial as bronchial thermoplasty (BT), despite its proven efficacy, safety and 
clinical effectiveness. We review and discuss BT best practice key points with the aim 
of: 1) fostering adoption by institutional leadership and 2) unifying BT skeptics and 
advocates in the health care industry. In addition, we provide strategies for increas-
ing asthma awareness in the public and medical communities by leveraging various 
facets of traditional as well as social media to ensure that patients and providers have 
legitimate access to BT.
Implementing a successful BT program
Three important areas should be the focus of any effort to bring BT to institutions and 
patients: 1) the alignment of clinical leadership and providers with current best practice 
recommendations to improve patient outcomes and safety, 2) lobbying local clinical 
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champions to protect provider and patient choice in treatment 
options, and 3) leveraging media to raise public awareness 
of advances in chronic disease management (including new 
therapeutics). All 3 areas are vital for patients and health care 
teams to reap the safety and benefits of clinical practice and 
experience in the era of cost containment (Figure 1).
Alignment of clinical leadership and 
providers
As technology grows at an accelerated rate, the medical com-
munity struggles to keep pace in the areas of electronic medi-
cal documentation and medical therapeutics. Although new 
medical devices and smart phone applications are welcomed 
by those who can adapt easily to technology, others resist these 
innovations. Unfortunately, the adoption of such a technology, 
for example, BT for the treatment of severe asthmatics, can 
be a difficult and frustrating experience to both patient and 
provider, particularly when there is misalignment of views 
between leadership within the hospital and health care provid-
ers, including pulmonologists and allergists. Unifying these 
views requires being an asthma patient advocate and having 
an appreciation of the dangers to asthmatics who continue 
to live a poor quality of life with frequent exacerbations 
despite adherence to conventional pharmacotherapies, allergy 
shots, removal of asthma triggers (i.e., tobacco smoke, dust, 
gastroesophageal reflux disease), assurance of good inhaler 
technique and compliance to prescribed inhaler medications. 
For some, scientific rationale, clinical trials and/or best practice 
guidelines are a sufficient basis for change. For others, only the 
objective improvement of their personal patients will turn their 
minds toward acceptance of BT as a viable treatment strategy.
Resistance to BT arise from not fully understanding how 
BT benefits asthma patients at the pathophysiological level. 
While first described in 1922 by Hubert and Koessler in 
cases of fatal asthma, airway remodeling exists in varying 
degrees of asthma severity and in both the small and large 
airways.1 Airway remodeling refers to the structural changes 
in the airways of the asthmatic subjects that are not typi-
cally present in healthy subjects. Structural changes include 
the loss of epithelial integrity, thickening of the basement 
membrane, subepithelial fibrosis, goblet cell and submucosal 
gland enlargement, increased smooth muscle mass, decreased 
cartilage integrity and increased airway vascularity.1–3 Such 
changes are primarily a result of ongoing chronic inflamma-
tion that involves multiple inflammatory pathways, including 
CD4+ T-cells, interleukins (IL-4, IL-5, IL-13), eosinophils, 
neutrophils and mast cells.4 Other factors include the duration 
of uncontrolled asthma, (often associated with reduced lung 
function), increased airway hyperresponsiveness (AHR) and 
asthma symptoms, as well as increased utilization of asthma 
therapy medications.5–7 BT significantly changes pathologic 
airway remodeling by decreasing the hypertrophied smooth 
muscle mass, airway inflammation, neuroendocrine epithe-
lial cells and bronchial nerve endings. It improves asthma 
symptom control ostensibly by decreasing bronchospasm and 
AHR.8,9 (Figure 2A and B, biopsy specimens taken before 
and 3 months after BT; note that Figure 2B, rather than rep-
resenting the average, exemplifies a case in which smooth 
muscle was virtually absent).9
As a validated adjunct to the armamentarium of available 
asthma therapy, BT provides hope for the 5%–10% defined as 
severe asthmatics refractory to conventional therapy.10–12 Still 
largely thought to be innovative, BT debuted in 2010 when 
















Figure 1 Key elements surrounding a successful BT program.
Abbreviation: BT, bronchial thermoplasty.
A
Figure 2 Structural effects of BT in bronchial biopsy specimens from patients with 
severe asthma. 
Notes: (A) Specimen taken before BT. (B) Specimen taken 3 months after BT (this 
image, rather than representing the average, exemplifies a case in which smooth 
muscle was virtually absent). Scale bars =250 μm.
Abbreviations: BT, bronchial thermoplasty; sm, smooth muscle.
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(FDA).11 A multi-centered, randomized, sham bronchoscopy 
controlled trial by Castro et al demonstrated that BT improved 
asthma symptom score based on the Asthma Quality of Life 
Questionnaire and other secondary end points (percentage 
of symptom-free days, total symptom core, forced expiratory 
volume 1 second, peak expiratory flow, rescue medication 
use) at 1 year.11,13 A Cochrane review on BT for moderate or 
severe persistent asthma in adults found that BT provided 
a modest clinical benefit in quality of life and lower rates 
of asthma exacerbation, but no significant difference in 
asthma control scores.14 Careful follow-up of >85% of the 
BT group out to 5 years demonstrated that the reduction in 
severe exacerbation seen in year 1 was maintained with no 
safety concerns.12 The paucity of BT programs available to 
asthma patients in the USA is evidence of the misalignment 
of views as to the safety and efficacy of BT in the real world. 
Cost-mediated health care decisions by hospital administra-
tors and insurance companies often discount the needs of the 
individual asthmatic and the long-term benefits to all patients 
over time, including the reduction in need for controller 
medications and a decrease in the frequency of acute exac-
erbations. Commonly held views by asthmatologists include 
the perception that BT does not affect airway inflammation 
and that only bronchodilators have any effect on the target 
tissue for BT: bronchial smooth muscle. Leaving difficult-
to-control patients on life-long biologics, prednisone and/or 
high-dose inhaled corticosteroids is neither completely safe 
nor financially and medically justifiable if the patient remains 
not well controlled or very poorly controlled.
The treatment of all asthma patients should be supported 
by the most convincing available evidence of safety and effi-
cacy. BT is not a cure for asthma but it is safe and effective in 
enhancing control over asthma symptoms and acute exacerba-
tions. BT is advocated for the treatment of severe asthma by 
the American College of Chest Physicians (CHEST), Asthma 
and Allergy Foundation of America (AAFA), American Col-
lege of Asthma, Allergy and Immunology (ACCAI), British 
Thoracic Society (BTS), and the Global Initiative for Asthma 
(GINA), which is an international consensus program that 
presents recommendations for comprehensive asthma man-
agement strategies.15–19 The United States National Institutes 
of Health National Asthma Education and Prevention Pro-
gram guidelines for clinical practice guidelines have not been 
updated since 2007, before BT was FDA-approved.
Nevertheless, the role of BT continues to be debated 
by the medical asthma community and insurance compa-
nies continue to deny authorization of payment. Aligning 
clinical leaders and providers of asthma treatment on the 
 understanding of the: 1) pathophysiology of asthma; 2) effect 
of BT on airway remodeling; 3) clinical trial data supporting 
BT; and 4) medical professional societies supporting its use, 
will help BT to gain greater acceptance and help admin-
istrators and insurance companies who hold overwhelm-
ing financial and political powers in health care resource 
decision-making to invest in BT.
Lobbying clinical champions
All health care decisions should be patient-centered. How-
ever, it is apparent that all health care decisions rely heav-
ily on the cost-mediated factors. Adoption of BT at any 
institution can be arduous, but offsetting the hard work are 
patient outcomes that can be extremely rewarding. Clinical 
champions are key to overcoming barriers and establishing a 
successful BT program. Within each group or division lies a 
political agenda, financial barriers, personal bias, organiza-
tional agendas, and reluctance to change. Being familiar with 
the organizational arena and tone provides further insight on 
how to create a successful program. Lobbying key thought 
leaders about BT and recruiting clinical champions is vital 
in promoting further support. Prior to fostering awareness, 
identification of community need for BT must also be con-
sidered. Asthma prevalence was reported to have increased 
from 7.3% in 2001 to 7.7% for 2014.20 Of the 25 million 
asthmatics, 5%–10% (~1.2–2.4 million) have been reported 
to have severe persistent asthma, asthma that is refractory 
to available standard oral and inhaled therapies.5 Although 
the needs for BT in a community may not on the surface 
appear to reflect the national prevalence, the magnitude of 
the problem may very well be unmasked with BT awareness. 
Within 8 months of starting our BT program at Loma Linda 
University, we have become the referral site for 3 neighbor-
ing hospitals and surrounding clinics. In addition, we have 
provided a validated therapeutic option to the asthma treat-
ment pathway for our pediatric asthma colleagues for when 
their patients turn 18. In the Northern California Central 
Valley, UC Davis remains the only university-based center 
for BT utilizing a patient care-centered pathway for refer-
rals (Figure 3).
As is true for most new technologies, upfront and ongoing 
financial expenditures concern all health care administrators, 
insurers, patients and health care providers. Establishing a 
BT program requires lobbying clinical champions to inform 
all stakeholders that business models for BT have demon-
strated it to be cost-effective and potentially cost-saving.21,22 
Most importantly, BT is a vital alternative in asthma patient-
centered care.





BT requires the individual clinician to depart from a linear 
and traditional mode of treatment and consider a therapy that 
some view as disruptive. It was “out-of-the-box,” forward 
thinking that made it possible to provide BT as an additional 
modality for asthmatics who have failed conventional therapy. 
Frequent and regular group discussions of plan of care for 
the most pressing and refractory asthmatic cases in a practice 
setting can foster thought-provoking discussions, which may 
highlight the need for stopping or beginning therapy that are 
outside the usual asthma regiment. Sharing our experience 
and some of our most remarkable BT cases can provide the 
incentive to accept change during a clinical trial of one.
Recognizing the national and community needs, mon-
etary advantages and acquiescence to progressive asthma 
therapies provide insufficient inertia unless a consistent force 
of “passion” is applied to fuel the drive in providing hope 
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Figure 3 UC Davis Health System ROAD™ Center Asthma Exacerbation and UCAN Referral Algorithm.
Note: Data from Mintz et al30 and Reddel et al.31
Abbreviations: √, to check; ABG, arterial blood gas; ACT, asthma control test; BT, bronchial thermoplasty; CHF, congestive heart failure; CXR, chest X-ray; DLco, diffusing 
capacity of the lungs for carbon monoxide; ER, emergency room; FEV1, forced expiratory volume 1 second; IgE, immunoglobulin E; MI, myocardial infarction; PE, pulmonary 
embolism; PEF, peak expiratory flow; PFT, pulmonary function test; PNA, pneumonia; PRN, as needed; PTX, pneumothorax; r/o, rule out; RAST, radioallergosorbent test; 
RN, registered nurse; ROAD, reversible obstructive airway disease; UC, University of California; UCAN, University of California Davis Asthma Network; w/o, without.
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to severe asthmatics. It is the instinct of competence, trust, 
emotional awareness, integrity, open communication and 
reliability that coalesce to form a passion to construct and 
sustain a successful BT program. Such attributes, in addition 
to life changing patient–physician case studies23 of post-BT 
patients, assist in persuading skeptical minds in favor of BT 
and other pulmonary therapies.
Leveraging media to raise public 
awareness
Leveraging asthma awareness utilizing social media plat-
forms  as well as media (television, newspapers, radio, inter-
net) provides a broad communication platform for health care 
professionals to reach patients within the community. This 
almost ubiquitous presence allows one to reach patients on 
their terms. Social media has altered the landscape of modern 
medicine24 but has also provided a means of transparency 
and connection, which is particularly germane in the realm 
of asthma therapy. The community became aware of our 
asthma clinic at Loma Linda University through medical 
education segments we provided to local television news 
agencies,25 through clinical insight to newspaper agencies26 
and most recently utilizing Facebook live chat to discuss 
asthma and its affiliated therapies. Through this platform, 
we promoted asthma awareness to over 17,000 people with 
6200 video views.
The portmanteau glocal (global and local), epitomizes 
our thoughts and efforts regarding asthma management and 
treatments. Circumspection back to the basics of asthma 
prompts review that asthma develops through the interac-
tion of genetic factors with environmental exposures. Strong 
evidence has linked exposure to allergens commonly found in 
homes, such as those derived from dust mites, cockroaches, 
rodents, molds, and pet dander, to sensitization and subse-
quent asthma incidence and morbidity. In addition to aller-
gens, other indoor asthma triggers include tobacco smoke, 
nitrogen oxides from combustion devices, and irritants from 
volatile organic compounds and fungi.27 Many patients in our 
communities in Southern California and Northern California 
do not have the luxury to move and avoid some of the most 
common allergens known to exacerbate asthma. Others have 
companion pets and would rather experience a near-death 
asthma exacerbation than abstaining from being around them. 
Air pollution is a contributing culprit and for decades has 
been associated with asthma exacerbations, emergency room 
visits, transitory reductions in lung function, and respiratory 
symptoms.27,28 Allergic responses have also been associated 
with pollutant exposure. While several pollutants have been 
associated with these outcomes, particulate air pollution has 
been extremely problematic.28 California was most recently 
in its sixth year of severe drought, the state also experienced 
multiple record-shattering heat waves. The combination of 
dry foliage with extreme dry heat has led to an increase in 
airborne particulate matter from uncontrolled wildfires, and 
together with other sources of pollutants (such as emissions 
from cars and factories) has created a seasonal ozone that 
can be caustic to any lung.26 Understanding and anticipat-
ing global trends in temperature, weather, ozone and air 
particulate levels can better assist in attending the cyclical 
community needs in asthma treatment, and in some cases, 
explicates a patient’s continuous and severe refractory asthma 
symptoms. We anticipate that BT will be of greatest value to 
asthma patients residing in cities where environmental chal-
lenges are the greatest. At present, only a failure to control 
asthma symptoms and risks with conventional pharmaco-
therapy identify candidates for BT.
Discussion and conclusion
Increasingly, hospitals are leveraging formal technology 
appraisals and evidence review processes prior to the pur-
chase of new technologies and onboarding of new services. 
However, while these reviews will ensure an open-eyed 
understanding of the technology and service, it is insuffi-
cient to ensure success. Best practice success should also be 
weighted on the community impact for treatment of poorly 
controlled severe, persistent asthma utilizing BT and its 
potential to reduce both health care resources and financial 
burden.21,22,29 Although the practicing allergist and pulmon-
ologists can do much to ensure success post-approval, the 3 
key strategies described above (alignment of clinical leader-
ship and providers, lobbying local clinical champions and 
leveraging media to raise public awareness) can exponentially 
enhance the likelihood of success.
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